

# Single Cell Analysis Market by Product (Consumables (Beads, Kits, Reagents), Instruments), Cell Type (Human, Animal), Technique (Flow Cytometry, NGS, PCR, Microscopy), Application (Research (Cancer, Neurology), Medical (NIPT, IVF)) - Global Forecast to 2030

Market Report | 2025-05-07 | 518 pages | MarketsandMarkets

# **AVAILABLE LICENSES:**

- Single User \$4950.00
- Multi User \$6650.00
- Corporate License \$8150.00
- Enterprise Site License \$10000.00

# Report description:

The single-cell analysis market is projected to reach USD 7.56 billion by 2030 from an estimated USD 3.81 billion in 2025, at a CAGR of 14.7% during the forecast period. This market growth is largely driven by the increasing emphasis on personalized medicine. Rising research & development investments in the pharmaceutical and biotechnology industries also contribute to the expansion of single-cell analysis. Additionally, factors such as growth in stem cell research and advancements in single-cell analysis technologies are expected to further boost the market. Furthermore, the increasing incidence of cancer is creating a demand for advanced therapies, which is anticipated to enhance the growth of the single-cell analysis market. The rising adoption of advanced single-cell sequencing techniques is also expected to propel market growth in the coming years.

"The research applications segment accounted for the largest share of the market segment in 2024."

The single-cell analysis market is divided into two main categories based on applications: research and medical applications. The research application segment includes various fields such as cancer research, immunology research, neurology research, stem cell research, and other related areas. In contrast, the medical applications segment is further divided into non-invasive prenatal diagnosis, in vitro fertilization, and circulating tumor cell detection.

In 2024, the research applications segment held the largest share of the global single-cell analysis market. The increasing prevalence of cancer is driving the demand for advanced therapies, which contributes to the growth of this segment. Additionally, the expansion of stem cell research is also expected to further boost the growth of the single-cell analysis market.

"The flow cytometry segment accounted for a major share of the market in 2024."

The single-cell analysis market is categorized based on technology into several segments: flow cytometry, next-generation

Scotts International. EU Vat number: PL 6772247784

sequencing, polymerase chain reaction, microscopy, mass spectrometry, and other techniques. In 2024, the flow cytometry segment was the largest contributor to the global single-cell analysis market by technology. This significant growth is primarily due to the widespread use of flow cytometry in single-cell analysis, as it can perform multiple measurements within a heterogeneous mixture. Furthermore, the increasing adoption of advanced cell identification and characterization technologies is expected to further drive growth in this segment of the single-cell analysis market.

"The US dominated the single-cell analysis market in 2024."

The single-cell analysis market is divided into six major regions: North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa. In 2024, the US dominated this market in North America. As the world's largest biopharmaceutical market, the US leads in biopharmaceutical research and investments. Its robust healthcare infrastructure further supports research & development in the life sciences sector. Additionally, the presence of numerous biopharmaceutical companies and increasing research activities in the biotechnology industry are contributing to market growth in the US. Furthermore, the rising focus on developing personalized medicine, driven by the increasing incidence of cancer, is also boosting the growth of the single-cell analysis market.

The primary interviews conducted for this report can be categorized as follows:

- By Respondent: Supply Side (70%) and Demand Side (30%)
- By Designation: Managers (45%), CXOs & Directors (30%), and Executives (25%)
- By Region: North America (40%), Europe (25%), Asia Pacific (25%), Latin America (5%), and Middle East & Africa (5%) List of Companies Profiled in the Report:
- Thermo Fisher Scientific Inc. (US)
- -□Danaher Corporation (US)
- -□Merck KGaA (Germany)
- -∏BD (US)
- -□Agilent Technologies, Inc. (US)
- -□QIAGEN (Netherlands)
- -[10x Genomics (US)
- -∏Illumina, Inc. (US)
- -□Bio-Rad Laboratories, Inc. (US)
- -∏DiaSorin S.p.A. (Italy)
- -∏Standard BioTools (US)
- Tecan Trading AG (Switzerland)
- -□Sartorius AG (Germany)
- -□Corning Incorporated (US)
- Cytek Biosciences (US)
- Takara Bio Inc. (Japan)
- -□bioMerieux (France)
- -□Revvity (US)
- -□Bio-Techne (US)
- -□PacBio (US)
- -∏Bruker (US)
- -□Promega Corporation (US)
- -□Oxford Nanopore Technologies plc. (UK)
- -□The Menarini Group (Italy)
- Singleron Biotechnologies (Germany)

Scotts International, EU Vat number: PL 6772247784

- -∏BICO (Sweden)
- -□Fluent BioSciences (US)
- RareCyte, Inc. (US)
- -□Cell Microsystems (US)
- -□NanoCellect Biomedical (US)
- -∏Apogee Flow Systems Ltd. (UK)
- Creative Biolabs (US)
- -□Sphere Bio (UK)
- Yokogawa Electric Corporation (Japan)

### Research Coverage:

This research report categorizes the single-cell analysis market by product {consumables [reagents, assay kits (immunoassays and cell-based assays), beads, microplates, and other consumables] and instruments (PCR instruments, NGS systems, flow cytometers, spectrophotometers, cell counters, microscopes, HCS systems, microarrays, and other instruments)}, cell type (human cells, animal cells, and microbial cells), technique (flow cytometry, next-generation sequencing, microscopy, polymerase chain reaction, mass spectrometry, and other techniques), application [research applications (cancer research, immunology research, neurology research, stem cell research, and other research applications) and medical applications (non-invasive prenatal diagnosis, in vitro fertilization, and circulating tumour cell detection)], end user (academic & research laboratories, biotechnology & pharmaceutical companies, hospitals & diagnostic laboratories, and cell banks & IVF centers), and region (North America, Europe, Asia Pacific, Latin America, the Middle East, and Africa). The scope of the report covers detailed information regarding the major factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the single-cell analysis market. A thorough analysis of the key industry players has been done to provide insights into their business overview, products, key strategies, collaborations, partnerships, and agreements. Also, it includes new product launches, collaborations, acquisitions, and recent developments associated with the single-cell analysis market.

### Key Benefits of Buying the Report:

The report will help market leaders and new entrants by providing the closest approximations of the revenue numbers for the overall single-cell analysis market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to better position their businesses and make suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide them with information on the key market drivers, restraints, opportunities, and challenges.

The report provides insights on the following pointers:

- Analysis of key drivers (technological advancements in single-cell analysis products, the surge in cases of cancer, and increasing R&D in pharmaceutical & biotechnology industries for complex diseases), restraints (high cost of single-cell analysis products), opportunities (integration of microfluidics in single-cell analysis), and challenges (standardization of protocols and data integration & quality control for developing cell therapies) influencing the growth of the market
- Product Development/Innovation: Detailed insights on newly launched products of the single-cell analysis market
- Market Development: Comprehensive information about lucrative markets; the report analyzes the market across varied regions
- Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the single-cell analysis market
- Competitive Assessment: Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), Merck KGaA (Germany), BD (US), Agilent Technologies, Inc. (US), QIAGEN (Netherlands), 10x Genomics (US), Illumina, Inc. (US), Bio-Rad Laboratories, Inc. (US), DiaSorin S.p.A. (Italy), Standard BioTools (US), Tecan Trading AG (Switzerland), Sartorius AG (Germany), Corning Incorporated (US), Cytek Biosciences (US), Takara Bio Inc. (Japan), bioMerieux (France), Revvity (US), Bio-Techne (US), PacBio (US), Bruker (US), Promega Corporation (US), Oxford Nanopore Technologies plc. (UK), The Menarini Group (Italy), Singleron Biotechnologies (Germany), BICO (Sweden), Fluent BioSciences (US), RareCyte, Inc. (US), Cell Microsystems (US), NanoCellect Biomedical (US), Apogee Flow Systems Ltd. (UK), Creative Biolabs (US) Sphere Bio (UK), and Yokogawa Electric Corporation (Japan)

# **Table of Contents:**

Scotts International, EU Vat number: PL 6772247784

# 1 INTRODUCTION 47

- 1.1 STUDY OBJECTIVES 47
- 1.2 MARKET DEFINITION 47
- 1.3 STUDY SCOPE 47
- 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE 48
- 1.3.2 YEARS CONSIDERED 49
- 1.3.3 INCLUSIONS AND EXCLUSIONS ☐ 49
- 1.4 CURRENCY CONSIDERED 50
- 1.5 STAKEHOLDERS 51
- 1.6 SUMMARY OF CHANGES 151
- 2 ⊓RESEARCH METHODOLOGY П52
- 2.1 RESEARCH DATA 52
- 2.1.1□SECONDARY DATA□53
- 2.1.2 PRIMARY DATA 53
- 2.2 MARKET SIZE ESTIMATION METHODOLOGY 55
- 2.2.1 □GLOBAL SINGLE-CELL ANALYSIS MARKET SIZE ESTIMATION □55
- 2.2.2□INSIGHTS FROM PRIMARY EXPERTS□57
- 2.2.3 TOP-DOWN APPROACH 58
- 2.3 MARKET GROWTH RATE PROJECTIONS 59
- 2.4 MARKET BREAKDOWN AND DATA TRIANGULATION 61
- 2.5 RESEARCH ASSUMPTIONS 62
- 2.6 RISK ANALYSIS 62
- 2.7 RESEARCH LIMITATIONS ☐ 62
- 3 EXECUTIVE SUMMARY 64
- 4□PREMIUM INSIGHTS□68
- 4.1 TATTRACTIVE OPPORTUNITIES FOR PLAYERS IN SINGLE-CELL ANALYSIS MARKET 68
- 4.2∏NORTH AMERICA: SINGLE-CELL ANALYSIS MARKET, BY CELL TYPE AND COUNTRY∏69
- 4.3 SINGLE-CELL ANALYSIS MARKET, BY PRODUCT, 2025 VS. 2030 69
- 4.4□SINGLE-CELL ANALYSIS MARKET, BY END USER□70
- 4.5 SINGLE-CELL ANALYSIS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 70

?

- 5∏MARKET OVERVIEW∏71
- 5.1∏INTRODUCTION∏71
- 5.2 MARKET DYNAMICS 71
- 5.2.1 DRIVERS 73
- 5.2.1.1 Technological advancements in single-cell analysis products 73
- 5.2.1.2 Rising prevalence of cancer 74
- 5.2.1.3∏Increasing R&D in pharmaceutical and biotechnology industries ☐75
- 5.2.1.4 Growth in stem cell research 76
- 5.2.1.5 Growing focus on personalized medicine 78
- 5.2.2 RESTRAINTS 79
- 5.2.2.1 High cost of single-cell analysis products 79
- 5.2.3∏OPPORTUNITIES∏80
- 5.2.3.1 High growth potential of single-cell sequencing 80
- 5.2.3.2 Integration of microfluidics in single-cell analysis 80
- 5.2.3.3 Rising potential in emerging Asian markets 81
- 5.2.4 CHALLENGES 81

Scotts International. EU Vat number: PL 6772247784

- 5.2.4.1 Lack of standardization in protocols and quality control procedures 81
- 5.2.4.2 Technical limitations of single-cell analysis 82
- 5.2.4.3 Mounting ethical and privacy concerns 82
- 5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER BUSINESS 82
- 5.4 VALUE CHAIN ANALYSIS 83
- 5.5 ECOSYSTEM ANALYSIS 85
- 5.6 TECHNOLOGY ANALYSIS 88
- 5.6.1 KEY TECHNOLOGIES 88
- 5.6.1.1 Flow cytometry 88
- 5.6.1.2 Next-generation sequencing 88
- 5.6.1.3 Polymerase chain reaction 89
- 5.6.1.4∏Microscopy∏89
- 5.6.1.5 Mass spectrometry 90
- 5.6.2 COMPLEMENTARY TECHNOLOGIES 90
- 5.6.2.1 Bioinformatics tools and computational analysis 90
- 5.6.2.2 | Multi-omics integration | 91
- 5.6.3 ADJACENT TECHNOLOGIES 92
- 5.6.3.1 Nanotechnology 92
- 5.6.3.2 Artificial intelligence and machine learning 92
- 5.7∏PATENT ANALYSIS∏92
- 5.7.1 | METHODOLOGY | 92
- 5.7.2 PATENTS APPLIED AND GRANTED, 2014-2024 92

?

- 5.8 TRADE ANALYSIS 95
- 5.8.1 IMPORT DATA (HS CODE 9027) □95
- 5.8.2 EXPORT DATA (HS CODE 9027) 97
- 5.9 PORTER'S FIVE FORCES ANALYSIS 99
- 5.9.1 THREAT OF NEW ENTRANTS 100
- 5.9.2 THREAT OF SUBSTITUTES 100
- 5.9.3 BARGAINING POWER OF SUPPLIERS 100
- 5.9.4 BARGAINING POWER OF BUYERS 100
- 5.9.5 | INTENSITY OF COMPETITIVE RIVALRY | 101
- 5.10 TARIFF & REGULATORY LANDSCAPE 101
- 5.10.1 TARIFF DATA (HS CODE 9027) 101
- 5.10.2 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 102
- 5.10.3 REGULATORY FRAMEWORK 105
- 5.11 □ PRICING ANALYSIS □ 108
- 5.11.1 AVERAGE SELLING PRICE TREND OF PRODUCTS, BY KEY PLAYERS 108
- 5.11.2 □ AVERAGE SELLING PRICE OF PRODUCTS, BY REGION □ 108
- 5.12 KEY CONFERENCES AND EVENTS, 2025-2026 109
- 5.13 KEY STAKEHOLDERS AND BUYING CRITERIA 110
- 5.13.1 KEY STAKEHOLDERS IN BUYING PROCESS 110
- 5.13.2 ROLE OF STAKEHOLDERS IN BUYING PROCESS 110
- 5.13.3 BUYING CRITERIA 111
- 5.14 INVESTMENT AND FUNDING SCENARIO 112
- 5.15 IMPACT OF GENERATIVE AI ON SINGLE-CELL ANALYSIS MARKET 113
- 5.15.1 | AI USE-CASES | 114

# Scotts International, EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 5.15.2 KEY COMPANIES IMPLEMENTING AI 115
- 5.16 CASE STUDY ANALYSIS 115
- 5.16.1 COMPREHENSIVE SINGLE? CELL TRANSCRIPTOMIC ATLAS OF HUMAN CORNEA 115
- 5.16.2∏MASSIVELY PARALLEL SINGLE-CELL RNA SEQUENCING IDENTIFIES RARE DRUG-RESISTANT CANCER SUBPOPULATIONS∏115
- 5.16.3 SINGLE-CELL ANALYSIS OF RENAL CELL CARCINOMA REVEALS TUMOR HETEROGENEITY AND MICROENVIRONMENTAL

### COMPLEXITY □116

- 5.17 US 2025 TARIFF IMPACT OVERVIEW 116
- 5.17.1 INTRODUCTION 116
- 5.17.2 KEY TARIFF RATES 117
- 5.17.3 PRICE IMPACT ANALYSIS 118
- 5.17.4 KEY IMPACT ON VARIOUS REGIONS 119
- 5.17.4.1∏US∏119
- 5.17.4.2 | Europe | 119
- 5.17.4.3 Asia Pacific 119
- 5.17.4.4 Rest of the World 120
- 5.17.5 END-USE INDUSTRY IMPACT 120
- 5.17.5.1 Pharmaceutical and biotech companies 120
- 5.17.5.2 Contract research organizations (CROs) 120
- 5.17.5.3 Academic & research institutes 121
- 6□SINGLE-CELL ANALYSIS MARKET, BY APPLICATION□122
- 6.1 INTRODUCTION 123
- 6.2 RESEARCH APPLICATIONS 123
- 6.2.1 CANCER RESEARCH 127
- 6.2.1.1 Rising prevalence of cancer to drive market 127
- 6.2.2□IMMUNOLOGY RESEARCH□130
- 6.2.2.1 High incidence of immunological disorders to propel market 130
- 6.2.3 NEUROLOGY RESEARCH 133
- 6.2.3.1 Increasing incidence of neurological disorders to boost market 133
- 6.2.4□STEM CELL RESEARCH□136
- 6.2.4.1 Rising investments in stem cell research to drive market 136
- 6.2.5 OTHER RESEARCH APPLICATIONS 139
- 6.3 | MEDICAL APPLICATIONS | 142
- 6.3.1 □NON-INVASIVE PRENATAL DIAGNOSIS □ 145
- 6.3.1.1 Increasing prevalence of genetic diseases to drive demand 145
- 6.3.2 IN VITRO FERTILIZATION 149
- 6.3.2.1 Growing demand for IVF procedures to support market 149
- 6.3.3 CIRCULATING TUMOR CELL DETECTION 152
- 6.3.3.1 Rising prevalence of cancer to contribute to segment growth 152
- 7 SINGLE-CELL ANALYSIS MARKET, BY CELL TYPE □ 155
- 7.1 INTRODUCTION 156
- 7.2 HUMAN CELLS 156
- 7.2.1 $\sqcap$ GROWING FUNDING FOR CANCER RESEARCH TO BOOST DEMAND $\square$ 156
- 7.3∏ANIMAL CELLS∏159
- 7.3.1 INCREASING ANIMAL CELL RESEARCH TO DRIVE MARKET 159
- 7.4.1 RISING GOVERNMENT SUPPORT TO COMBAT ANTIMICROBIAL RESISTANCE TO PROPEL MARKET 162
- 8 SINGLE-CELL ANALYSIS MARKET, BY END USER 166

Scotts International. EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 8.1 INTRODUCTION 167
- 8.2 ACADEMIC & RESEARCH LABORATORIES 167
- 8.2.1 | INCREASING FUNDING FOR LIFE SCIENCE RESEARCH TO DRIVE MARKET | 167
- 8.3 BIOTECHNOLOGY & PHARMACEUTICAL COMPANIES 171
- 8.3.1 GROWTH IN DRUG DISCOVERY AND R&D ACTIVITIES TO BOOST MARKET 171
- 8.4 HOSPITALS & DIAGNOSTIC LABORATORIES 174
- 8.4.1 HIGH PREVALENCE OF INFECTIOUS AND CHRONIC DISEASES TO DRIVE DEMAND 174
- 8.5 | CELL BANKS & IVF CENTERS | 178
- 8.5.1 RISING DEMAND FOR PERSONALIZED AND REGENERATIVE MEDICINE TO PROPEL MARKET 178
- 9∏SINGLE-CELL ANALYSIS MARKET, BY PRODUCT∏182
- 9.1∏INTRODUCTION∏183
- 9.2□CONSUMABLES□183
- 9.2.1 | BEADS | 186
- 9.2.1.1 Increasing use in research and genetic exploration to drive market 186
- 9.2.2 MICROPLATES 189
- 9.2.2.1 Rising frequency of product launches to boost market 189
- 9.2.3 REAGENTS 192
- 9.2.3.1 Advancements in single-cell genomics to increase demand 192
- 9.2.4 ASSAY KITS 195
- 9.2.4.1∏Immunoassays∏198
- 9.2.4.1.1 Growth in geriatric population to fuel demand 198
- 9.2.4.2 Cell-based assays 200
- 9.2.4.2.1 Increasing use in pharma and biopharma companies to drive market 200
- 9.2.5 OTHER CONSUMABLES 203
- 9.3 INSTRUMENTS 206
- 9.3.1 FLOW CYTOMETERS 209
- 9.3.1.1 Technological advancements to drive demand 209
- 9.3.2 NGS SYSTEMS 213
- 9.3.2.1 Increased affordability to support segment growth 213
- 9.3.3 ☐ PCR INSTRUMENTS ☐ 216
- 9.3.3.1 Rising use for DNA and mRNA amplification to boost market 216
- 9.3.4 SPECTROPHOTOMETERS 1218
- 9.3.4.1 Technological advancements to boost market 218
- 9.3.5 CELL COUNTERS 221
- 9.3.5.1 Rising demand for automated cell counters to fuel market 221
- 9.3.6 MICROSCOPES 224
- 9.3.6.1 Increasing use in cell-based research to drive market 224
- 9.3.7 HCS SYSTEMS 227
- $9.3.7.1 \\ \square Growing \ need \ for \ multi-parametric \ cell \ analysis \ to \ drive \ adoption \\ \square 227$
- 9.3.8∏MICROARRAYS∏229
- 9.3.8.1 Increasing development of targeted therapies to support market I229
- $9.3.9 \verb||OTHER INSTRUMENTS|| 232$

?

- 10 SINGLE-CELL ANALYSIS MARKET, BY TECHNIQUE 236
- 10.1□INTRODUCTION□237
- 10.2 $\square$ FLOW CYTOMETRY $\square$ 237
- 10.2.1 INCREASING USE TO IDENTIFY CANCEROUS CELLS TO DRIVE MARKET 237

Scotts International, EU Vat number: PL 6772247784

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 10.3 NEXT-GENERATION SEQUENCING 241
- 10.3.1 WIDE ADOPTION IN DRUG DISCOVERY TO DRIVE MARKET 241
- 10.4 POLYMERASE CHAIN REACTION 244
- 10.4.1 INCREASING APPLICATIONS OF DIGITAL PCR TO SUPPORT MARKET 244
- 10.5 MICROSCOPY 247
- 10.5.1 FOCUS ON DEVELOPMENT OF ADVANCED IMAGING SYSTEMS TO PROPEL MARKET 247
- 10.6 MASS SPECTROMETRY 250
- 10.6.1 LAUNCH OF ADVANCED PRODUCTS TO DRIVE MARKET 250
- 10.7 OTHER TECHNIQUES 253
- 11 SINGLE-CELL ANALYSIS MARKET, BY REGION 257
- 11.1□INTRODUCTION□258
- 11.2 NORTH AMERICA 258
- 11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 1263
- 11.2.2 US 264
- 11.2.2.1 Increasing R&D investments and funding to drive market □264
- 11.2.3 CANADA 269
- 11.2.3.1 High prevalence of hemophilia to propel market 269
- 11.3 EUROPE 273
- 11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 277
- 11.3.2 | GERMANY | 278
- 11.3.2.1 Growing awareness of advanced cell therapies to support market 278
- 11.3.3 UK 282
- 11.3.3.1 Growing adoption of single-cell analysis products to drive demand 282
- 11.3.4 FRANCE 286
- 11.3.4.1 Growing government funding for R&D to propel market 286
- 11.3.5 | ITALY | 290
- 11.3.5.1 Focus on cell biology research to drive market 290
- 11.3.6 SPAIN 294
- 11.3.6.1 Increasing number of biotechnology companies to drive demand 294
- 11.3.7 REST OF EUROPE 298
- 11.4 ASIA PACIFIC 303
- 11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 308
- 11.4.2□CHINA□309
- 11.4.2.1 ☐ Increasing R&D expenditure to support market ☐ 309
- 11.4.3∏APAN∏313
- 11.4.3.1 □Increasing geriatric population to fuel demand □313
- 11.4.4 INDIA 317
- 11.4.4.1 Growing focus on development of cell-based therapies to boost market 317
- 11.4.5 SOUTH KOREA 321
- 11.4.5.1 | Increasing number of strategic alliances to boost market | 321
- 11.4.6∏AUSTRALIA∏325
- 11.4.6.1 Rising number of life science companies to boost demand 325
- 11.4.7 ⊓REST OF ASIA PACIFIC □ 329
- 11.5 LATIN AMERICA 333
- 11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 337
- 11.5.2∏BRAZIL∏338
- 11.5.2.1 Rising focus on biotechnology industry to bolster market 338

tel. 0048 603 394 346 e-mail: support@scotts-international.com

- 11.5.3 MEXICO 342
- 11.5.3.1 Government support for biopharmaceutical production to drive market 342
- 11.5.4□REST OF LATIN AMERICA□346
- 11.6 MIDDLE EAST 350
- 11.6.1 MACROECONOMIC OUTLOOK IN MIDDLE EAST 354
- 11.6.2 | GCC | 355
- 11.6.2.1 Saudi Arabia 359
- 11.6.2.1.1 ☐ Increasing healthcare expenditure to drive market ☐ 359
- 11.6.2.2 United Arab Emirates 363
- 11.6.2.2.1 ☐ Advancements in biopharmaceutical sector to drive demand ☐ 363
- 11.6.2.3 Rest of GCC 367
- 11.6.3 REST OF MIDDLE EAST 371
- 11.7∏AFRICA∏375
- 11.7.1 GROWING FUNDING FOR DEVELOPMENT AND PRODUCTION OF BIOPHARMACEUTICALS TO DRIVE MARKET 375
- 11.7.2 MACROECONOMIC OUTLOOK FOR AFRICA 379
- 12 COMPETITIVE LANDSCAPE 381
- 12.1□OVERVIEW□381
- 12.2 KEY PLAYER STRATEGIES/RIGHT TO WIN, 2021-2025 381
- 12.3 REVENUE ANALYSIS, 2022-2024 386
- 12.4 MARKET SHARE ANALYSIS, 2024 387
- 12.4.1 RANKING OF KEY MARKET PLAYERS 389
- 12.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 389
- 12.5.1 STARS 389
- 12.5.2 EMERGING LEADERS 389
- 12.5.3 PERVASIVE PLAYERS 390
- 12.5.4 PARTICIPANTS 390
- 12.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 391
- 12.5.5.1 Company footprint 391
- 12.5.5.2 Product footprint 392
- 12.5.5.3 Region footprint 393
- 12.5.5.4 Technique footprint 394
- 12.5.5.5 | Application footprint | 395
- 12.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023 396
- 12.6.1 PROGRESSIVE COMPANIES 396
- 12.6.2 RESPONSIVE COMPANIES 396
- 12.6.3 DYNAMIC COMPANIES 396
- 12.6.4 STARTING BLOCKS 396
- 12.6.5 COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2024 398
- 12.6.5.1 Detailed list of key startups/SMEs 398
- 12.6.5.2 Competitive benchmarking of key startups/SMEs 399
- 12.7 COMPANY VALUATION AND FINANCIAL METRICS 400
- 12.8 BRAND/PRODUCT COMPARISON 401
- 12.9

  ☐COMPETITIVE SCENARIO☐403
- 12.9.1 PRODUCT LAUNCHES 403
- 12.9.2 DEALS 405
- 12.9.3 EXPANSIONS 407
- 13 COMPANY PROFILES 408

tel. 0048 603 394 346 e-mail: support@scotts-international.com

www.scotts-international.com

- 13.1∏INTRODUCTION∏408
- 13.2 KEY PLAYERS 408
- 13.2.1∏BD∏408
- 13.2.1.1 Business overview 408
- 13.2.1.2 Products offered 409
- 13.2.1.3 Recent developments 411
- 13.2.1.3.1 Product launches 411
- 13.2.1.3.2 Deals 412
- 13.2.1.4 MnM view 412
- 13.2.1.4.1 Key strengths 412
- 13.2.1.4.2 Strategic choices 413
- 13.2.1.4.3 Weaknesses and competitive threats 413
- 13.2.2 THERMO FISHER SCIENTIFIC INC. 414
- 13.2.2.1 Business overview 414
- 13.2.2.2 Products offered 415
- 13.2.2.3 Recent developments 418
- 13.2.2.3.1 Product launches 418
- 13.2.2.3.2 Deals 418
- 13.2.2.4 MnM view 419
- 13.2.2.4.1 Key strengths 419
- 13.2.2.4.2 Strategic choices 419
- 13.2.2.4.3 Weaknesses and competitive threats 419
- 13.2.3 DANAHER CORPORATION 420
- 13.2.3.1 Business overview 420
- 13.2.3.2 Products offered 421
- 13.2.3.3 Recent developments 423
- 13.2.3.3.1 Deals 423
- 13.2.3.4 MnM view 424
- 13.2.3.4.1 Key strengths 424
- 13.2.3.4.2 Strategic choices 424
- 13.2.3.4.3 Weaknesses and competitive threats 424
- 13.2.4 □ 10X GENOMICS □ 425
- 13.2.4.1

  ☐ Business overview
  ☐ 425
- 13.2.4.2 Products offered 427
- 13.2.4.3 Recent developments 428
- $13.2.4.3.1 \verb|| Product launches \verb||| 428$
- 13.2.4.3.2 Deals 429
- 13.2.5 MERCK KGAA 431
- $13.2.5.1 \verb||Business overview|| 431$
- 13.2.5.2 Products offered 432
- 13.2.5.3 Recent developments 434
- 13.2.5.3.1 Deals 434
- 13.2.6 ☐ AGILENT TECHNOLOGIES, INC. ☐ 435
- 13.2.6.1 Business overview 435
- 13.2.6.2 Products offered 436
- 13.2.6.3 Recent developments 438
- 13.2.6.3.1 Product launches 438

- 13.2.6.3.2 Deals 439
- 13.2.7 QIAGEN 440
- 13.2.7.1 Business overview 440
- 13.2.7.2 Products offered 442
- 13.2.7.3 Recent developments 443
- 13.2.7.3.1 Deals 443
- 13.2.8 ILLUMINA, INC. 444
- 13.2.8.1 Business overview 444
- 13.2.8.2 Products offered 445
- 13.2.8.3 Recent developments 447
- 13.2.8.3.1 Product launches 447
- 13.2.8.3.2 Deals 447
- 13.2.9 BIO-RAD LABORATORIES, INC. 449
- 13.2.9.1 Business overview 449
- 13.2.9.2 Products offered 451
- 13.2.9.3 Recent developments 453
- 13.2.9.3.1 Product launches 453
- 13.2.10 DIASORIN S.P.A. 454
- 13.2.10.1 Business overview 454
- 13.2.10.2 Products offered 456
- 13.2.10.3 Recent developments 456
- 13.2.10.3.1Deals456
- 13.2.11 STANDARD BIOTOOLS 457
- 13.2.11.1 Business overview 457
- 13.2.11.2 Product offered 458
- 13.2.11.3 Recent developments 459
- 13.2.11.3.1 Product launches 459
- 13.2.11.3.2 Deals 460
- 13.2.12 TECAN TRADING AG 461
- 13.2.12.1 Business overview 461
- 13.2.12.2 Products offered 462
- 13.2.12.3 Recent developments 463
- 13.2.12.3.1 Product launches 463
- 13.2.12.3.2 Deals 463
- 13.2.13 SARTORIUS AG 464
- 13.2.13.1 Business overview 464
- 13.2.13.2 Products offered 465
- 13.2.13.3 Recent developments 466
- $13.2.13.3.1 \verb|| Deals \verb||| 466$
- 13.2.13.3.2 Expansions 466
- 13.2.14 CORNING INCORPORATED 467
- 13.2.14.1 Business overview 467
- 13.2.14.2 Products offered 468
- 13.2.15 ☐ CYTEK BIOSCIENCES ☐ 469
- 13.2.15.1 Business overview 469
- $13.2.15.2 \verb|| Products offered \verb||| 470$
- 13.2.15.3 Recent developments 470

- $13.2.15.3.1 \verb| | Product launches \verb| | | 470$
- 13.2.15.3.2 Deals 471
- 13.2.15.3.3 Expansions 471
- 13.2.16 TAKARA BIO INC. 472
- 13.2.16.1 Business overview 472
- 13.2.16.2 Products offered 473
- 13.2.16.3 Recent developments 475
- 13.2.16.3.1 Product launches 475
- 13.2.16.3.2Deals475

?

- 13.2.17∏BIOMERIEUX∏476
- 13.2.17.1 Business overview 476
- 13.2.17.2 Products offered 477
- 13.2.17.3 Recent developments 478
- 13.2.17.3.1 Deals 478
- 13.2.18 REVVITY 479
- 13.2.18.1 Business overview 479
- 13.2.18.2 Products offered 480
- 13.2.18.3 Recent developments 482
- 13.2.18.3.1 Deals 482
- 13.2.19 BIO-TECHNE 483
- 13.2.19.1 Business overview 483
- 13.2.19.2 Products offered 484
- 13.2.19.3 Recent developments 485
- 13.2.19.3.1 Deals 485
- 13.2.20 PACBIO 486
- 13.2.20.1 Business overview 486
- 13.2.20.2 Products offered 487
- 13.2.20.3 Recent developments 487
- 13.2.20.3.1 Product launches 487
- 13.2.21 BRUKER 488
- 13.2.21.1 Business overview 488
- 13.2.21.2 Products offered 490
- 13.2.21.3 Recent developments 491
- 13.2.21.3.1 Product launches 491
- 13.2.21.3.2 Deals 492
- 13.2.22 PROMEGA CORPORATION 493
- 13.2.22.1 Business overview 493
- 13.2.22.2 Products offered 493
- 13.2.23 OXFORD NANOPORE TECHNOLOGIES PLC 495
- 13.2.23.1 Business overview 495
- 13.2.23.2 Products offered 496
- 13.2.23.3 Recent developments 497
- 13.2.23.3.1 Deals 497
- 13.3 OTHER PLAYERS 498
- 13.3.1 SINGLERON BIOTECHNOLOGIES 498
- 13.3.2□CELL MICROSYSTEMS□499

# Scotts International, EU Vat number: PL 6772247784

- 13.3.3 NANOCELLECT BIOMEDICAL 500
- 13.3.4 RARECYTE, INC. 501
- 13.3.5 BICO 502
- 13.3.6 MENARINI GROUP 503
- 13.3.7 APOGEE FLOW SYSTEMS LTD 504
- 13.3.8 CREATIVE BIOLABS 505
- 13.3.9∏SPHERE BIO∏506
- 13.3.10 YOKOGAWA ELECTRIC CORPORATION 507
- 14

  APPENDIX

  508
- 14.1 DISCUSSION GUIDE 508
- 14.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL 514
- 14.3 CUSTOMIZATION OPTIONS 516
- 14.4□RELATED REPORTS□516
- 14.5 AUTHOR DETAILS 517



To place an Order with Scotts International:

☐ - Complete the relevant blank fields and sign

☐ - Print this form

# Single Cell Analysis Market by Product (Consumables (Beads, Kits, Reagents), Instruments), Cell Type (Human, Animal), Technique (Flow Cytometry, NGS, PCR, Microscopy), Application (Research (Cancer, Neurology), Medical (NIPT, IVF)) - Global Forecast to 2030

Market Report | 2025-05-07 | 518 pages | MarketsandMarkets

select license	License				Price
	Single User				\$4950.00
	Multi User				\$6650.00
	Corporate License				\$8150.00
	Enterprise Site License				\$10000.00
				VAT	
				Total	
	ant license option. For any questions pleas at 23% for Polish based companies, individ				
* VAT will be added a		luals and EU based co			
* VAT will be added a					
		luals and EU based co			
** VAT will be added a		luals and EU based co			
** VAT will be added a mail* irst Name*		luals and EU based co	ompanies who are unable		

**Scotts International. EU Vat number: PL 6772247784** tel. 0048 603 394 346 e-mail: support@scotts-international.com

Zip Code*	Country*	
	Date	2025-05-20
	Signature	